New Hepatitis C Drug Combinations | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Triple Therapy Reduces Hepatitis C Drug Resistance

Back to News Homepage
Next

Hep C Update: New Evidence for Milk Thistle

New Hepatitis C Drug Combinations

The Editors at Hepatitis Central
March 11, 2010

Print this page

Combined with interferon and ribavirin, clinical trials on Vertex’s telaprevir demonstrate twice the success rate in clearing Hepatitis C in half the time as traditional combination therapy. While this alone is exciting, Vertex is exploring a range of drug combination options for battling the Hepatitis C virus.

Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C

Luke Timmerman 3/8/10

HIV has taught the pharmaceutical industry that the best way to fight an infectious virus that resists a single drug is to make a cocktail that attacks the virus in more than one way. Vertex Pharmaceuticals and its competitors are now following a similar formula with new therapies for hepatitis C.

Vertex, the Cambridge, MA-based company with operations in San Diego, offered a glimpse last week into its strategy for a two-drug combo that could significantly change hepatitis C treatment. If the company has mapped this out correctly, it could rid people of the virus while letting them ditch the detested standard therapies that force them to endure months of flu-like symptoms.

Continue reading this entire article:
http://www.xconomy.com/boston/2010/03/08/vertex-maps-out-combo-drug-as-new-game-plan-for-treating-hepatitis-c/

No Comments - be the first!
Share
Share
Previous

Triple Therapy Reduces Hepatitis C Drug Resistance

Back to News Homepage
Next

Hep C Update: New Evidence for Milk Thistle

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.